Understanding how tumors depend on certain proteins and resist drugs at a single cell level
Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level
['FUNDING_U01'] · COLUMBIA UNIVERSITY HEALTH SCIENCES · NIH-10925184
This study is looking at the proteins that help tumors grow and survive, especially how they can make cancer harder to treat, so we can find better ways to help more cancer patients respond to treatment.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | COLUMBIA UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10925184 on ClinicalTrials.gov |
What this research studies
This research investigates the specific proteins that tumors rely on for growth and survival, particularly focusing on how these proteins can lead to drug resistance. By examining cancer cells at a single-cell level, the study aims to identify both oncogene dependencies, which are directly involved in tumor growth, and non-oncogene dependencies, which can be targeted for treatment. The approach involves analyzing the tumor's transcriptional state and how it adapts to therapies, with the goal of developing more effective treatment strategies that could benefit a wider range of cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with various types of cancers, particularly those who have not responded well to existing therapies.
Not a fit: Patients with tumors that do not exhibit the identified dependencies or those who are not actively undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that target the underlying dependencies of tumors, potentially improving outcomes for patients.
How similar studies have performed: Other research has shown promise in targeting tumor dependencies, but this approach focusing on single-cell analysis and mutation-agnostic strategies is relatively novel.
Where this research is happening
NEW YORK, UNITED STATES
- COLUMBIA UNIVERSITY HEALTH SCIENCES — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CALIFANO, ANDREA — COLUMBIA UNIVERSITY HEALTH SCIENCES
- Study coordinator: CALIFANO, ANDREA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.